Status:
COMPLETED
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
B-cell Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission
Eligibility:
All Genders
Up to 17 years
Brief Summary
This laboratory study is looking at response or resistance to chemotherapy in young patients with acute lymphoblastic leukemia treated with methotrexate. Studying samples of tumor tissue in the labora...
Detailed Description
OBJECTIVES: I. Determine the molecular basis for human reduced folate carrier (hRFC) transcripts in B-precursor and T-cell acute lymphoblastic leukemia (ALL) blasts obtained from children with newly ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of B-precursor or T-cell acute lymphoblastic leukemia
- Newly diagnosed disease subsequently treated with methotrexate
- Banked diagnostic blast specimens are available from Childrens Oncology Group (COG) cellbank
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2016
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00898404
Start Date
November 1 2003
End Date
May 1 2016
Last Update
May 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Oncology Group
Arcadia, California, United States, 91006-3776